drugset / Trial / NCT03513172

Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy

NCT03513172

RandomizedCrossoverTriple-blindPrevention

Summary

In this study, investigators will be examining the intraocular pressure lowering effect of brimonidine 0.15% when administered 20min prior to intravitreal anti-VEGF injection.

Timeline

Start
2016-12-15
Primary completion
2017-07-15
Completion
2017-09-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brimonidine Small molecule 0.15 % Topical

Indications